BY MARKETWIRE
-
Coloplast expects organic growth and profit margin in new financial year on par with last year
In the previous fiscal year, Coloplast recognized a natural development of 8%.
-
Ambu grows less than outlook – forecast points to slightly lower gear
Once More, it was the Endoscopy Solutions service system that drove the majority of the development.
-
Strong retail business limits Q3 disappointment for Demant
While other business areas disappointed, the retail business performed surprisingly well in the recent quarter.
-
Analysts expect conservative Ambu outlook – focus on increasing competition
Though Ambu has raised its steering twice within the present fiscal 12 months, analysts anticipate one other cautious forecast from the corporate when it releases its annual report…
-
EU opens investigation into Novo’s Catalent acquisition
The EU is releasing an examination right into the bargain in between Novo Holdings and Catalent after the Danish investment firm reqested authorization of the purchase.
-
Coloplast wants to be gauged on outlook, new product sales and potential US sales
Sales growth of Coloplast’s latest marketed items, Luja and Heylo, will certainly a centerpiece for experts in Coloplast’s yearly record, where a number of various othe…
-
Obesity underdog releases new data, reaps stock exchange rewards
On the Robinhood exchange system, Viking Rehabs’ share rate leapt 21% to USD 88 on Monday early morning. Its rival to Novo Nordisk and Eli Lilly’s successful weight pro…
-
Novo Nordisk’s semaglutide shown to reduce pain from knee osteoarthritis
Semaglutide is the energetic component in Novo Nordisk’s diabetes mellitus medication Ozempic and the weight problems medication Wegovy.
-
Lundbeck closer to launching Vyepti in Asia after Phase 3 success
Vyepti is currently authorized in the United States and the EU for the therapy of migraine headache.
-
Eli Lilly to advertise obesity drug in the US
The project is anticipated to start in November.
